Market news

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Moby summary of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call

By John Vandermosten, CFA NYSE: PLX READ THE FULL PLX RESEARCH REPORT Second Quarter 2026 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE: PLX) surprised to the upside with a strong quarter of sales for Elfabrio, generating revenues of over $14 million for the product in 2Q:26. The result vaulted total revenues to almost $20 million, which helped tip earnings into positive

Revenue climbs 27% year-over-year, driven by higher Elfabrio sales to Chiesi, while the company advances its promising PRS-115 gout program.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the second quarter ended June 30, 2026, and provided a business and clinical update.

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended June 30, 2026 and provide a business update on August 12, 2026.